Recent developments on treatment strategies and the prognosis of dermatomyositis: a review

References

• Volc-Platzer B. [Dermatomyositis-update]. Hautarzt. 2015;66:604–610.
   PubMed Web of Science ®Google Scholar
• Callen JP. Cutaneous manifestations of dermatomyositis and their management. Curr Rheumatol Rep. 2010;12:192–197.
   PubMedGoogle Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292:344–347.
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403–407.
   PubMed Web of Science ®Google Scholar
• Gerami P, Schope JM, McDonald L, et al. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006;54:597–613.
   PubMed Web of Science ®Google Scholar
• Bendewald MJ, Wetter DA, Li X, et al. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol. 2010;146:26–30.
   PubMedGoogle Scholar
• Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet (London, England). 2001; 357:96–100.
   PubMed Web of Science ®Google Scholar
• Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer. 2001;85:41–45.
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, Lindelof B, Edhag O, et al. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med. 1992;326:363–367.
   PubMed Web of Science ®Google Scholar
• Fathi M, Dastmalchi M, Rasmussen E, et al. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis. 2004;63:297–301.
   PubMed Web of Science ®Google Scholar
• Yamasaki Y, Yamada H, Ohkubo M, et al. Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. J Rheumatol. 2011;38:1636–1643.
   PubMed Web of Science ®Google Scholar
• Ikeda S, Arita M, Misaki K, et al. Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study. SpringerPlus. 2015;4:240.
   PubMed Web of Science ®Google Scholar
• Hirakata M, Nagai S. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol. 2000;12:501–508.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Kikuchi T, Takada T. Mycophenolate mofetil for the patients with interstitial lung diseases in amyopathic dermatomyositis with anti-MDA-5 antibodies. Clin Rheumatol. 2017;36:239–240.
   PubMed Web of Science ®Google Scholar
• Gerfaud-Valentin M, Ahmad K, Piegay F, et al. [Interstitial lung disease-associated with amyopathic dermatomyositis and anti-MDA5 autoantibodies]. Rev Mal Respir. 2014;31:849–853.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Aoki A, Asakawa K, et al. Cytokine profiles of amyopathic dermatomyositis with interstitial lung diseases treated with mycophenolate. Respirol Case Rep. 2017;5:e00235.
   PubMed Web of Science ®Google Scholar
• Silveira MG, Selva-O'Callaghan A, Ramos-Terrades N, et al. Anti-MDA5 dermatomyositis and progressive interstitial pneumonia. QJM. 2016;109:49–50.
   PubMed Web of Science ®Google Scholar
• Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005;52:1571–1576.
   PubMed Web of Science ®Google Scholar
• Deakin CT, Yasin SA, Simou S, et al. Muscle biopsy findings in combination with myositis-specific autoantibodies aid prediction of outcomes in juvenile dermatomyositis. Arthritis Rheumatol. (Hoboken, NJ). 2016;68:2806–2816.
   PubMed Web of Science ®Google Scholar
• Koyama RVL, Braga TKK, da Silva Dias GA, et al. Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case-based review. Clin Rheumatol. 2017;36:1919–1926.
   PubMed Web of Science ®Google Scholar
• Iorizzo LJ, 3rd, Jorizzo JL. The treatment and prognosis of dermatomyositis: an updated review. J Am Acad Dermatol. 2008;59:99–112.
   PubMed Web of Science ®Google Scholar
• Quartier P, Gherardi RK. Juvenile dermatomyositis. Handb Clin Neurol. 2013;113:1457–1463.
   PubMedGoogle Scholar
• Hoeltzel MF, Oberle EJ, Robinson AB, et al. The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis. Curr Rheumatol Rep. 2014;16:467.
   PubMed Web of Science ®Google Scholar
• Sallum AM, Pivato FC, Doria-Filho U, et al. Risk factors associated with calcinosis of juvenile dermatomyositis. J Pediatr (Rio J). 2008;84:68–74.
   PubMed Web of Science ®Google Scholar
• Sallum AM, Kiss MH, Sachetti S, et al. Juvenile dermatomyositis: clinical, laboratorial, histological, therapeutical and evolutive parameters of 35 patients. Arq Neuro-Psiquiatr. 2002;60:889–899.
   PubMed Web of Science ®Google Scholar
• Gunawardena H, Wedderburn LR, Chinoy H, et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum. 2009;60:1807–1814.
   PubMed Web of Science ®Google Scholar
• Tansley SL, Betteridge ZE, Shaddick G, et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology (Oxford, England). 2014;53:2204–2208.
   PubMed Web of Science ®Google Scholar
• Vermaak E, Tansley SL, McHugh NJ. The evidence for immunotherapy in dermatomyositis and polymyositis: a systematic review. Clin Rheumatol. 2015;34:2089–2095.
   PubMed Web of Science ®Google Scholar
• Bronner IM, van der Meulen MF, de Visser M, et al. Long-term outcome in polymyositis and dermatomyositis. Ann Rheum Dis. 2006;65:1456–1461.
   PubMed Web of Science ®Google Scholar
• Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for dermatomyositis. J Am Acad Dermatol. 1996;34(5 Pt 1):824–829.
   Web of Science ®Google Scholar
• Sunderkotter C, Nast A, Worm M, et al. Guidelines on dermatomyositis-excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology. J Dtsch Dermatol Ges. 2016;14:321–338.
   PubMed Web of Science ®Google Scholar
• Marie I, Mouthon L. Therapy of polymyositis and dermatomyositis. Autoimmun Rev. 2011;11:6–13.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol. 2010;6:129–137.
   PubMed Web of Science ®Google Scholar
• Genth E. [Inflammatory muscle diseases: dermatomyositis, polymyositis, and inclusion body myositis]. Internist (Berl). 2005;46:1218–1232.
   PubMed Web of Science ®Google Scholar
• Dalakas MC. Inflammatory myopathies: management of steroid resistance. Curr Opin Neurol. 2011;24:457–462.
   PubMed Web of Science ®Google Scholar
• Hak AE, de Paepe B, de Bleecker JL, et al. Dermatomyositis and polymyositis: new treatment targets on the horizon. Neth J Med. 2011;69:410–421.
   PubMed Web of Science ®Google Scholar
• Seshadri R, Feldman BM, Ilowite N, et al. The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum. 2008;59:989–995.
   PubMed Web of Science ®Google Scholar
• Enders FB, Bader-Meunier B, Baildam E, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76:329–340.
   PubMed Web of Science ®Google Scholar
• Kishi T, Miyamae T, Hara R, et al. Clinical analysis of 50 children with juvenile dermatomyositis. Mod Rheumatol. 2013;23:311–317.
   PubMed Web of Science ®Google Scholar
• Sinha A, Bagga A. Pulse steroid therapy. Indian J Pediatr. 2008;75:1057–1066.
   PubMed Web of Science ®Google Scholar
• Huber AM, Robinson AB, Reed AM, et al. Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference. Arthritis Care Res. 2012;64:546–553.
   PubMed Web of Science ®Google Scholar
• Dawkins MA, Jorizzo JL, Walker FO, et al. Dermatomyositis: a dermatology-based case series. J Am Acad Dermatol. 1998;38:397–404.
   PubMed Web of Science ®Google Scholar
• Jorizzo JL. Dermatomyositis: practical aspects. Arch Dermatol. 2002;138:114–116.
   PubMedGoogle Scholar
• Johnson NE, Arnold WD, Hebert D, et al. Disease course and therapeutic approach in dermatomyositis: a four-center retrospective study of 100 patients. Neuromuscul Disord. 2015;25:625–631.
   PubMed Web of Science ®Google Scholar
• Findlay AR, Goyal NA, Mozaffar T. An overview of polymyositis and dermatomyositis. Muscle Nerve. 2015;51:638–656.
   PubMed Web of Science ®Google Scholar
• Fendler C, Braun J. Use of methotrexate in inflammatory myopathies. Clin Exp Rheumatol. 2010;28(5 Suppl 61):S164–S167.
   Web of Science ®Google Scholar
• Mira-Avendano IC, Parambil JG, Yadav R, et al. A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis/dermatomyositis. Respir Med. 2013;107:890–896.
   PubMed Web of Science ®Google Scholar
• Hornung T, Ko A, Tuting T, et al. Efficacy of low-dose methotrexate in the treatment of dermatomyositis skin lesions. Clin Exp Dermatol. 2012;37:139–142.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Pistorio A, Oliveira S, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet (London, England). 2016;387:671–678.
   PubMed Web of Science ®Google Scholar
• Hengstman GJ, De Bleecker JL, Feist E, et al. Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol. 2008;59:159–163.
   PubMed Web of Science ®Google Scholar
• Vencovsky J, Jarosova K, Machacek S, et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol. 2000;29:95–102.
   PubMed Web of Science ®Google Scholar
• Go DJ, Park JK, Kang EH, et al. Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease. Rheumatol Int. 2016;36:125–131.
   PubMed Web of Science ®Google Scholar
• Kotani T, Makino S, Takeuchi T, et al. Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. J Rheumatol. 2008;35:254–259.
   PubMed Web of Science ®Google Scholar
• Suda T, Fujisawa T, Enomoto N, et al. Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J. 2006;28:1005–1012.
   PubMed Web of Science ®Google Scholar
• Saito E, Koike T, Hashimoto H, et al. Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and dermatomyositis. Mod Rheumatol. 2008;18:34–44.
   PubMed Web of Science ®Google Scholar
• Marie I, Menard JF, Hatron PY, et al. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. Arthritis Care Res (Hoboken). 2010;62:1748–1755.
   PubMed Web of Science ®Google Scholar
• Yoshimatsu Y, Kotani T, Fujiki Y, et al. Successful treatment with intravenous high-dose immunoglobulin for cardiomyopathy in dermatomyositis complicated with rapid progressive interstitial pneumonia. Int J Rheum Dis. 2015. DOI: 10.1111/1756-185x.12746.
   PubMedGoogle Scholar
• Mizoguchi F, Takada K, Ishikawa K, et al. A case of dermatomyositis with rhabdomyolysis, rescued by intravenous immunoglobulin. Mod Rheumatol. 2015;25:646–648.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Hayakawa H, Miwa S, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung. 2009;187:201–206.
   PubMed Web of Science ®Google Scholar
• Takai M, Katsurada N, Nakashita T, et al. Rapidly progressive interstitial lung disease associated with dermatomyositis treated with combination of immunosuppressive therapy, direct hemoperfusion with a polymyxin B immobilized fiber column and intravenous immunoglobulin. Intern Med. 2015;54:2225–2229.
   PubMed Web of Science ®Google Scholar
• Koguchi-Yoshioka H, Okiyama N, Iwamoto K, et al. Intravenous immunoglobulin contributes to control anti-melanoma differentiation-associated protein 5 (MDA5) antibody-associated dermatomyositis with palmar violaceous macules/papules. Br J Dermatol. 2017. DOI:10.1111/bjd.15499.
   PubMed Web of Science ®Google Scholar
• Hamada-Ode K, Taniguchi Y, Kimata T, et al. High-dose intravenous immunoglobulin therapy for rapidly progressive interstitial pneumonitis accompanied by anti-melanoma differentiation-associated gene 5 antibody-positive amyopathic dermatomyositis. Eur J Rheumatol. 2015;2:83–85.
   PubMed Web of Science ®Google Scholar
• Foreman C, Russo P, Davies N, et al. Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients. Intern Med J. 2017;47:112–115.
   PubMed Web of Science ®Google Scholar
• Kampylafka EI, Kosmidis ML, Panagiotakos DB, et al. The effect of intravenous immunoglobulin (IVIG) treatment on patients with dermatomyositis: a 4-year follow-up study. Clin Exp Rheumatol. 2012;30:397–401.
   PubMed Web of Science ®Google Scholar
• Sanchez-Ramon S, Ravell JC, de la Torre I, et al. Long-term remission of severe refractory dermatopolymyositis with a weekly-scheme of immunoglobulin followed by rituximab therapy. Rheumatol Int. 2010;30:817–819.
   PubMed Web of Science ®Google Scholar
• Miyasaka N, Hara M, Koike T, et al. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Mod Rheumatol. 2012;22:382–393.
   PubMed Web of Science ®Google Scholar
• Linardaki G, Cherouvim E, Goni G, et al. Intravenous immunoglobulin treatment for pregnancy-associated dermatomyositis. Rheumatol Int. 2011;31:113–115.
   PubMed Web of Science ®Google Scholar
• Nozaki Y, Ikoma S, Funauchi M, et al. Respiratory muscle weakness with dermatomyositis during pregnancy: successful treatment with intravenous immunoglobulin therapy. J Rheumatol. 2008;35:2289.
   PubMed Web of Science ®Google Scholar
• NIH Consensus Conference. Intravenous immunoglobulin. Prevention and treatment of disease. JAMA. 1990;264:3189–3193.
   PubMed Web of Science ®Google Scholar
• Clemenz MR, McGowan Iv JW, Shuler MJ, et al. Intravenous immunoglobulin-induced hemolytic anemia in a patient with juvenile dermatomyositis. J Drugs Dermatol. 2013;12:111–113.
   PubMed Web of Science ®Google Scholar
• Emilie S, Dougados M, Nguyen M, et al. Acute renal failure after intravenous immunoglobulin therapy. Clin Exp Rheumatol. 2010;28:444.
   PubMed Web of Science ®Google Scholar
• Manlhiot C, Tyrrell PN, Liang L, et al. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content. Pediatrics. 2008;121:e626–e630.
   PubMed Web of Science ®Google Scholar
• Schleinitz N, Jean E, Benarous L, et al. Subcutaneous immunoglobulin administration: an alternative to intravenous infusion as adjuvant treatment for dermatomyositis? Clin Rheumatol. 2008;27:1067–1068.
   PubMed Web of Science ®Google Scholar
• Cherin P, Belizna C, Cartry O, et al. Long-term subcutaneous immunoglobulin use in inflammatory myopathies: A retrospective review of 19 cases. Autoimmun Rev. 2016;15:281–286.
   PubMed Web of Science ®Google Scholar
• Speth F, Haas JP, Hinze CH. Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases. Pediatr Rheumatol. 2016;14:52.
   PubMed Web of Science ®Google Scholar
• Danieli MG, Gelardi C, Pedini V, et al. Subcutaneous IgG in immune-mediate diseases: proposed mechanisms of action and literature review. Autoimmun Rev. 2014;13:1182–1188.
   PubMed Web of Science ®Google Scholar
• Danieli MG, Pettinari L, Moretti R, et al. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev. 2011;10:144–149.
   PubMed Web of Science ®Google Scholar
• Saunders P, Tsipouri V, Keir GJ, et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials. 2017;18:275.
   PubMed Web of Science ®Google Scholar
• Hildebrand BA, Jr, Arroyo R. Evolution of clinically amyopathic dermatomyositis despite aggressive immunosuppression with cyclophosphamide and prednisone. J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. 2010;16:143–145.
   Google Scholar
• Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res (Hoboken). 2010;62:1496–1501.
   PubMed Web of Science ®Google Scholar
• Saketkoo LA, Espinoza LR. Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects. Am J Med Sci. 2009;337:329–335.
   PubMed Web of Science ®Google Scholar
• Cozzani E, Cinotti E, Felletti R, et al. Amyopathic dermatomyositis with lung involvement responsive to mycophenolate mofetil. Immunopharmacol Immunotoxicol. 2013;35:687–692.
   PubMed Web of Science ®Google Scholar
• Tsuchiya H, Tsuno H, Inoue M, et al. Mycophenolate mofetil therapy for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis. Mod Rheumatol. 2014;24:694–696.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zheng Y. Pneumocystis jirovecii pneumonia in mycophenolate mofetil-treated patients with connective tissue disease: analysis of 17 cases. Rheumatol Int. 2014;34:1765–1771.
   PubMed Web of Science ®Google Scholar
• Kuczia P, Sokolowska B, Szczeklik W, et al. [Effective application of therapeutic plasma exchange in a case of acute dermatomyositis]. Przeglad Lekarski. 2012;69:1230–1231.
   PubMedGoogle Scholar
• Cozzi F, Marson P, Pigatto E, et al. Plasma-exchange as a “rescue therapy” for dermato/polymyositis in acute phase. Experience in three young patients. Transfus Apher Sci. 2015;53:368–372.
   PubMed Web of Science ®Google Scholar
• Kaieda S, Yoshida N, Yamashita F, et al. Successful treatment of macrophage activation syndrome in a patient with dermatomyositis by combination with immunosuppressive therapy and plasmapheresis. Mod Rheumatol. 2015;25:962–966.
   PubMed Web of Science ®Google Scholar
• Bustos BR, Carrasco AC, Toledo RC. [Plasmapheresis for macrophage activation syndrome and multiorgan failure as first presentation of juvenile dermatomyositis]. Anal Pediatr (Barcelona, Spain: 2003). 2012;77:47–50.
   PubMed Web of Science ®Google Scholar
• Mattar MA, Gualano B, Perandini LA, et al. Safety and possible effects of low-intensity resistance training associated with partial blood flow restriction in polymyositis and dermatomyositis. Arthritis Res Ther. 2014;16:473.
   PubMed Web of Science ®Google Scholar
• Alemo Munters L, Dastmalchi M, Katz A, et al. Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositis. Arthritis Res Ther. 2013;15:R83.
   PubMed Web of Science ®Google Scholar
• Habers GE, Bos GJ, van Royen-Kerkhof A, et al. Muscles in motion: a randomized controlled trial on the feasibility, safety and efficacy of an exercise training programme in children and adolescents with juvenile dermatomyositis. Rheumatology (Oxford, England). 2016;55:1251–1262.
   PubMed Web of Science ®Google Scholar
• Yokoyama Y, Furuta S, Ikeda K, et al. Corticosteroid-sparing effect of tacrolimus in the initial treatment of dermatomyositis and polymyositis. Mod Rheumatol. 2015;25:888–892.
   PubMed Web of Science ®Google Scholar
• Shimojima Y, Ishii W, Matsuda M, et al. Coadministration of tacrolimus with corticosteroid accelerates recovery in refractory patients with polymyositis/dermatomyositis: a retrospective study. BMC Musculoskelet Disord. 2012;13:228.
   PubMed Web of Science ®Google Scholar
• Matsubara S, Kondo K, Sugaya K, et al. Effects of tacrolimus on dermatomyositis and polymyositis: a prospective, open, non-randomized study of nine patients and a review of the literature. Clin Rheumatol. 2012;31:1493–1498.
   PubMed Web of Science ®Google Scholar
• Ueno KI, Shimojima Y, Kishida D, et al. Advantage of administering tacrolimus for improving prognosis of patients with polymyositis and dermatomyositis. Int J Rheum Dis. 2016;19:1322–1330.
   PubMed Web of Science ®Google Scholar
• Kurita T, Yasuda S, Oba K, et al. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology (Oxford, England). 2015;54:39–44.
   PubMed Web of Science ®Google Scholar
• Witt LJ, Demchuk C, Curran JJ, et al. Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease. Pulm Pharmacol Ther. 2016;36:46–52.
   PubMed Web of Science ®Google Scholar
• Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65:314–324.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Bandos A, Reed AM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol (Hoboken, NJ). 2014;66:740–749.
   PubMed Web of Science ®Google Scholar
• Reed AM, Crowson CS, Hein M, et al. Biologic predictors of clinical improvement in rituximab-treated refractory myositis. BMC Musculoskelet Disord. 2015;16:257.
   PubMed Web of Science ®Google Scholar
• Fiehn C, Unger L, Schulze-Koops H, et al. [Rituximab for the treatment of poly- and dermatomyositis: results from the GRAID-2 registry]. Z Rheumatol. 2017. DOI:10.1007/s00393-017-0327-z.
   Web of Science ®Google Scholar
• Rios Fernandez R, Callejas Rubio JL, Sanchez Cano D, et al. Rituximab in the treatment of dermatomyositis and other inflammatory myopathies. A report Of 4 cases And review Of The literature. Clin Exp Rheumatol. 2009;27:1009–1016.
   Google Scholar
• Kuye IO, Smith GP. The use of rituximab in the management of refractory dermatomyositis. J Drugs Dermatol. 2017;16:162–166.
   PubMed Web of Science ®Google Scholar
• Cuttner J, Spiera H, Gorevic P. Rituximab in refractory and relapsed dermatomyositis and polymyositis: comment on the article by Oddis et al. Arthritis Rheum. 2013;65:2497–2498.
   PubMedGoogle Scholar
• Mahler EA, Blom M, Voermans NC, et al. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology (Oxford, England). 2011;50:2206–2213.
   PubMed Web of Science ®Google Scholar
• Bader-Meunier B, Decaluwe H, Barnerias C, et al. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol. 2011;38:1436–1440.
   PubMed Web of Science ®Google Scholar
• Hisanaga J, Kotani T, Fujiki Y, et al. Successful multi-target therapy including rituximab and mycophenolate mofetil in anti-melanoma differentiation-associated gene 5 antibody-positive rapidly progressive interstitial lung disease with clinically amyopathic dermatomyositis. Int J Rheum Dis. 2017. DOI:10.1111/1756-185x.13136.
   PubMed Web of Science ®Google Scholar
• Koichi Y, Aya Y, Megumi U, et al. A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment. Mod Rheumatol. 2017;27:536–540.
   PubMed Web of Science ®Google Scholar
• Watanabe R, Ishii T, Araki K, et al. Successful multi-target therapy using corticosteroid, tacrolimus, cyclophosphamide, and rituximab for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis. Mod Rheumatol. 2016;26:465–466.
   PubMed Web of Science ®Google Scholar
• Eissa K, Palomino J. B-cell depletion salvage therapy in rapidly progressive dermatomyositis related interstitial lung disease. J La State Med Soc. 2016;168:99–100.
   PubMedGoogle Scholar
• Tokunaga K, Hagino N. Dermatomyositis with rapidly progressive interstitial lung disease treated with rituximab: a report of 3 cases in Japan. Intern Med. 2017;56:1399–1403.
   PubMed Web of Science ®Google Scholar
• Guo X, Higgs BW, Rebelatto M, et al. Suppression of soluble T cell-associated proteins by an anti-interferon-alpha monoclonal antibody in adult patients with dermatomyositis or polymyositis. Rheumatology (Oxford, England). 2014;53:686–695.
   PubMed Web of Science ®Google Scholar
• Higgs BW, Zhu W, Morehouse C, et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis. 2014;73:256–262.
   PubMed Web of Science ®Google Scholar
• A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol. 2011;70:427–436.
   PubMed Web of Science ®Google Scholar
• Rouster-Stevens KA, Ferguson L, Morgan G, et al. Pilot study of etanercept in patients with refractory juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2014;66:783–787.
   PubMed Web of Science ®Google Scholar
• Liu SW, Velez NF, Lam C, et al. Dermatomyositis induced by anti-tumor necrosis factor in a patient with juvenile idiopathic arthritis. JAMA Dermatol. 2013;149:1204–1208.
   PubMed Web of Science ®Google Scholar
• Klein R, Rosenbach M, Kim EJ, et al. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol. 2010;146:780–784.
   PubMed Web of Science ®Google Scholar
• Zou J, Li T, Huang X, et al. Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody. Ann Rheum Dis. 2014;73:1591–1593.
   PubMed Web of Science ®Google Scholar
• Arabshahi B, Silverman RA, Jones OY, et al. Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr. 2012;160:520–522.
   PubMed Web of Science ®Google Scholar
• Holzer U, van Royen-Kerkhof A, van der Torre P, et al. Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis. Scand J Rheumatol. 2010;39:88–92.
   PubMed Web of Science ®Google Scholar
• Levine T. Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series. Drug Des Dev Ther. 2012;6:133–139.
   PubMed Web of Science ®Google Scholar
• Wolff M, Mancuso C, Lal K, et al. Paraneoplastic dermatomyositis with cutaneous and myopathic disease responsive to adrenocorticotropic hormone therapy. J Clin Aesthet Dermatol. 2017;10:57–62.
   PubMedGoogle Scholar
• Kondo M, Murakawa Y, Matsumura T, et al. A case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis? Rheumatology (Oxford, England). 2014;53:1907–1908.
   PubMed Web of Science ®Google Scholar
• Boswell JS, Costner MI. Leflunomide as adjuvant treatment of dermatomyositis. J Am Acad Dermatol. 2008;58:403–406.
   PubMed Web of Science ®Google Scholar
• Sangle VS, Sangle SR, D'Cruz DP. Leflunomide as a remission-maintaining therapy in difficult-to-treat dermatomyositis. Ann Rheum Dis. 2008;67:723.
   PubMed Web of Science ®Google Scholar
• de Souza RC, de Souza FHC, Miossi R, et al. Efficacy and safety of leflunomide as an adjuvant drug in refractory dermatomyositis with primarily cutaneous activity. Clin Exp Rheumatol. Forthcoming.
   Web of Science ®Google Scholar
• Sontheimer RD. Dermatomyositis: an overview of recent progress with emphasis on dermatologic aspects. Dermatol Clin. 2002;20:387–408.
   PubMed Web of Science ®Google Scholar
• Ghate J, Katsambas A, Augerinou G, et al. Review article: a therapeutic update on dermatomyositis/polymyositis. Int J Dermatol. 2000;39:81–87.
   PubMed Web of Science ®Google Scholar
• Casado E, Gratacos J, Tolosa C, et al. Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients. Ann Rheum Dis. 2006;65:385–390.
   PubMed Web of Science ®Google Scholar
• Foulke G, Baccon J, Marks JG, et al. Antimalarial myopathy in amyopathic dermatomyositis. Arch Dermatol. 2012;148:1100–1101.
   PubMedGoogle Scholar
• Kim JE, Jeong MG, Lee HE, et al. Successful treatment of cutaneous lesions of dermatomyositis with topical pimecrolimus. Ann Dermatol. 2011;23:348–351.
   PubMed Web of Science ®Google Scholar
• Navarrete-Dechent C, Manriquez JJ, del Puerto C, et al. Brimonidine gel for the treatment of persistent heliotrope rash in a patient with amyopathic dermatomyositis: a case report. J Eur Acad Dermatol Venereol. 2016;30:476–477.
   PubMed Web of Science ®Google Scholar
• Kawachi Y, Fujisawa Y, Furuta J, et al. Pruritic poikilodermatous eruption associated with dermatomyositis: successful treatment with dapsone. Eur J Dermatol. 2012;22:289–290.
   PubMed Web of Science ®Google Scholar
• Ishibuchi H, Motegi S, Amano H, et al. Successful treatment with dapsone for skin lesions of amyopathic dermatomyositis. J Dermatol. 2015;42:1019–1021.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Loganathan P, Koontz D, et al. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology (Oxford, England). 2017;56:247–254.
   PubMed Web of Science ®Google Scholar
• Femia AN, Eastham AB, Lam C, et al. Intravenous immunoglobulin for refractory cutaneous dermatomyositis: a retrospective analysis from an academic medical center. J Am Acad Dermatol. 2013;69:654–657.
   PubMed Web of Science ®Google Scholar
• Bounfour T, Bouaziz JD, Bezier M, et al. Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease. J Eur Acad Dermatol Venereol. 2014;28:1150–1157.
   PubMed Web of Science ®Google Scholar
• Del Barrio-Diaz P, Moll-Manzur C, Alvarez-Veliz S, et al. Topical sodium metabisulfite for the treatment of calcinosis cutis: a promising new therapy. Br J Dermatol. 2016;175:608–611.
   PubMed Web of Science ®Google Scholar
• Pagnini I, Simonini G, Giani T, et al. Sodium thiosulfate for the treatment of calcinosis secondary to juvenile dermatomyositis. Clin Exp Rheumatol. 2014;32:408–409.
   PubMed Web of Science ®Google Scholar
• Smith GP. Intradermal sodium thiosulfate for exophytic calcinosis cutis of connective tissue disease. J Am Acad Dermatol. 2013;69:e146–e147.
   PubMed Web of Science ®Google Scholar
• Schanz S, Ulmer A, Fierlbeck G. Response of dystrophic calcification to intravenous immunoglobulin. Arch Dermatol. 2008;144:585–587.
   PubMedGoogle Scholar
• Shahani L. Refractory calcinosis in a patient with dermatomyositis: response to intravenous immune globulin. BMJ Case Rep. 2012. DOI:10.1136/bcr-2012-006629
   Google Scholar
• Kalajian AH, Perryman JH, Callen JP. Intravenous immunoglobulin therapy for dystrophic calcinosis cutis: unreliable in our hands. Arch Dermatol. 2009;145:334. author reply 335.
   PubMedGoogle Scholar
• Dubos M, Ly K, Martel C, et al. Is rituximab an effective treatment of refractory calcinosis? BMJ Case Rep. 2016. DOI:10.1136/bcr-2015-213179
   PubMedGoogle Scholar
• O'Leary PA, Waismann M. Dermatomyositis: a study of forty cases. Arch Dermatol Syphilol. 1940;41:1001–1019.
   Google Scholar
• Schiopu E, Phillips K, MacDonald PM, et al. Predictors of survival in a cohort of patients with polymyositis and dermatomyositis: effect of corticosteroids, methotrexate and azathioprine. Arthritis Res Ther. 2012;14:R22.
   PubMed Web of Science ®Google Scholar
• Yu KH, Wu YJ, Kuo CF, et al. Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases. Clin Rheumatol. 2011;30:1595–1601.
   PubMed Web of Science ®Google Scholar
• Maugars YM, Berthelot JM, Abbas AA, et al. Long-term prognosis of 69 patients with dermatomyositis or polymyositis. Clin Exp Rheumatol. 1996;14:263–274.
   PubMed Web of Science ®Google Scholar
• Danieli MG, Gambini S, Pettinari L, et al. Impact of treatment on survival in polymyositis and dermatomyositis. A single-centre long-term follow-up study. Autoimmun Rev. 2014;13:1048–1054.
   PubMed Web of Science ®Google Scholar
• Hashkes PJ, Wright BM, Lauer MS, et al. Mortality outcomes in pediatric rheumatology in the US. Arthritis Rheum. 2010;62:599–608.
   PubMed Web of Science ®Google Scholar